BCM-95® (CURCUGREEN®), 14 Aug 2021
Preethi Ravindranathan, Divya Pasham, Uthra Balaji, Jacob Cardenas, JinghuaGu, ShusukeToden & Ajay Goel
Introduction: Combining anti-cancer agents in cancer therapies is becoming increasingly popular due to improved efficacy, reduced toxicity and decreased emergence of resistance. Here, we test the hypothesis that dietary agents such as oligomeric proanthocyanidins (OPCs) and Curcumin cooperatively modulate cancer-associated cellular mechanisms to inhibit carcinogenesis.
Methods: By a series of in vitro assays in colorectal cancer cell lines, we showed that the anti-tumorigenic properties of the OPCs-Curcumin combination were superior to the effects of individual compounds. By RNA-sequencing based gene-expression profiling in six colorectal cancer cell lines, we identified the cooperative modulation of key cancer-associated pathways such as DNA replication and cell cycle pathways. Moreover, several pathways, including protein export, glutathione metabolism and porphyrin metabolism were more effectively modulated by the combination of OPCs and Curcumin. We validated genes belonging to these pathways, such as HSPA5, SEC61B, G6PD, HMOX1 and PDE3B to be cooperatively modulated by the OPCs-Curcumin combination. We further confirmed that the OPCs-Curcumin combination more potently suppresses colorectal carcinogenesis and modulated expression of genes identified by RNA-sequencing in mice xenografts and in colorectal cancer patient-derived organoids.
Results: Overall, by delineating the cooperative mechanisms of action of OPCs and Curcumin, we make a case for the clinical co-administration of Curcumin and OPCs as a treatment therapy for patients with colorectal cancer.